Blood transfusion: Friend or foe

AACN Advanced Critical Care

Volumn 20, Issue 2, 2009, Pages 155-163

  Katz, Elizabeth A ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Blood substitutes; Transfusion reaction; Transfusion associated circulatory overload; Transfusion related acute lung injury; Transfusion related immunomodulation

Indexed keywords

ARTICLE; BLOOD TRANSFUSION; CONTINUING EDUCATION; HUMAN;

BLOOD TRANSFUSION; EDUCATION, CONTINUING; HUMANS;

EID: 67650224973     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/NCI.0b013e3181a0d688     Document Type: Article

References (38)

1. AuBuchon J, Birkmeyer J, Busch M. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med. 1997;127:904-909.
2. Gernsheimer T. Transfusion therapy: blood components and transfusion complications. In: Irwin R, Rippe J, eds. Intensive Care Medicine. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:278-1283.
3. Schreiber G, Busch M, Kleinman S, Korelitz J. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996;334:1685-1690.
4. Goodnough L, Shander A, Brecher M. Transfusion medicine: looking to the future. Lancet. 2003;361:161-169.
5. Dzieczkowski J, Anderson K. Transfusion biology and therapy. In: Fauci A, Braunwald E, Kasper D, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw-Hill; 2008:707-713.
6. Carlson K, ed. AACN Advanced Critical Care Nursing. St Louis, MO: Saunders; 2008.
7. Heddle N. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol. 1999;6:420-426.
8. Domen R, Hoeltge G. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med. 2003;127:316-320.
9. Shivdasani R, Haluska F, Dock N, et al. Graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med. 1993;328: 766-770.
10. Silliman C, Boshkov L, Mehdizadehkashi Z, et al. Trans-fusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood. 2003; 101:454-462.
11. Zoon, K. Transfusion-related acute lung injury [letter]. http://www.fda.gov/cber/ltr/trali101901.htm. Published 2001. Accessed August 11, 2008.
12. Looney M, Gropper M, Matthay M. Transfusion-related acute lung injury: a review. Chest. 2004;126:249-258.
13. Sanchez R, Bacchetti P, Toy P. Transfusion-related acute lung injury: a case-control pilot study of risk factors. Am J Clin Pathol. 2007;128:128-134.
14. Mair D, Hirschler N, Eastlund T. Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). Crit Care Med. 2006;34:S137-S143.
15. Eder A, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47:599-607.
16. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med. 2007;35:1645-1648.
17. Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial of transfusion-related acute lung injury: Is plasma from multiparous blood donors dangerous? Transfusion. 2001;41:317-322.
18. Skeate R, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol. 2007; 14:682-687.
19. Gajic O, Gropper M, Hubmayr R. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med. 2006;34:S109-S113.
20. Fiebig E, Wu A, Krombach J, et al. Transfusion-related acute lung injury and transfusion-associated circulatory overload: mutually exclusive or coexisting entities? Transfusion. 2007;47:171-172.
21. Zhou L, Giacherio D, Cooling L, Davenport R. Use of Bnatriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion. 2005;45:1056-1063.
22. Vamvakas E, Blajchman M. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001;97:1180-1195.
23. Opelz G, Sengar D, Mickey M, Terasaki P. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973;5:253-259.
24. Raghavan M, Marik P. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest. 2005;127:295-307.
25. Lee T, Paglieroni T, Ohto H, Holland P, Busch M. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood. 1999; 93:3127-3139.
26. Jensen L, Andersen A, Christiansen P, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg. 1992;79:513-516.
27. Jensen L, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet. 1996;348:841-845.
28. Winslow R. Current status of blood substitute research: towards a new paradigm. J Intern Med. 2003;253: 508-517.
29. Henkel-Hanke T, Oleck M. Artificial oxygen carriers: a current review. AANA J. 2007;75:205-211.
30. Spahn D. Blood substitutes. Artificial oxygen carriers: perfluorocarbon emulsions. Crit Care. 1999;3:R93-R97.
31. Blood substitutes. http://biomed.brown.edu/Courses /BI108/2006- 108websites/group09artificialblood /Pages/oxygent.htm. Published 2006. Accessed September 3, 2008.
32. Cabrales P, Tsai A, Frangos J, Briceño J, Intaglietta M. Oxygen delivery and consumption in the microcirculation after extreme hemodilution with perfluorocarbons. Am J Physiol Heart Circ Physiol. 2004;287:H320-H330.
33. Northfield Laboratories Inc. http://northfieldlabs.com. Published 2008. Accessed August 28, 2008.
34. Tinmouth A, McIntyre L, Fowler R. Blood conservation strategies to reduce the need for red blood cell transfusion in critically ill patients. Can Med Assoc J. 2008;178: 49-57.
35. Alexander, E. Drug update: emerging role of recombinant factor VIIa in neuroscience. AACN Adv Crit Care. 2006;17:363-367.
36. Roberts H, Monroe D, White G. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-3864.
37. Lee L, DeBois W, Krieger K, Isom O. Transfusion therapy and blood conservation. In: Cohn L, ed. Cardiac Surgery in the Adult. New York: McGraw-Hill; 2008:415-430.
38. Ferraris V, Ferraris S, Saha S, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83:S27-S86.